Puma Biotechnology Inc PBYI
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2012-03-21 |
| Shares Out. | 50,900,000 |
| Website | pumabiotechnology.com/ ↗ |
| Phone | 13026587581 |
| Employees | 179 |
| Revenue | $44.8M |
| Gross Profit | $34.4M |
| Net Income | -$3.8M |
| Free Cash Flow | $53.6M |
| Total Assets | $192.7M |
| Total Liabilities | $64.3M |
| Equity | $128.4M |
About Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Puma Biotechnology Inc is a publicly traded company under the ticker symbol PBYI on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
6 analysts (2026-07-01)